Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverACIU
NasdaqGMUSD

AC Immune SA

$00123456789.0012345678900123456789-0.5%
52w low (est.) $1.76$2.83 52w high (est.)
Market data · updated 1h ago
Market data
52w range
USD2.03 - USD4.00
Beta
1.00
Sector
Unknown
Run the 10-point checklist before you buy How these numbers are made

About AC Immune SA

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, conformation specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome related AD; ACI-7104.056 to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it develops diagnostic programs consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589 and ACI-15916, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative diseases. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD; Morphomer a-syn to compete with small molecule inhibitors of a-syn aggregation; and NeuroOrphan Tauopathies. Additionally, it generates discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Valuation

Overall Rating
0
Not rated
Not rated
Moat Score0
DCF Intrinsic Value
Not covered by our valuation model yet.

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
USD0.00
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
0.0%
Profit Margin
0.0%
ROE
0.0%
Debt / Equity
0.00
Beta
1.00
vs Unknown sector:Moat 0 vs 0Yield 0.00% vs 0.0%

Statistics

Similar Stocks · Unknown

Latest News · ACIU